Company Analysis Adaptimmune Therapeutics plc
1. Summary
Advantages
- Price (0.055 $) is less than fair price (0.18 $)
Disadvantages
- Dividends (0%) are below the sector average (0.53%).
- The stock's return over the last year (-81.2%) is lower than the sector average (-48.03%).
- Current debt level 30.17% has increased over 5 years from 4.43%.
- The company's current efficiency (ROE=-275.74%) is lower than the sector average (ROE=104.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Adaptimmune Therapeutics plc | Healthcare | Index | |
|---|---|---|---|
| 7 days | 52.8% | 2.1% | -2.7% |
| 90 days | 52.8% | 10.7% | -1.9% |
| 1 year | -81.2% | -48% | 16.4% |
ADAP vs Sector: Adaptimmune Therapeutics plc has significantly underperformed the "Healthcare" sector by -33.17% over the past year.
ADAP vs Market: Adaptimmune Therapeutics plc has significantly underperformed the market by -97.57% over the past year.
Stable price: ADAP is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ADAP with weekly volatility of -1.56% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.055 $) is lower than the fair price (0.18 $).
Price significantly below the fair price: The current price (0.055 $) is 227.3% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-0.28) is lower than that of the sector as a whole (36.09).
P/E vs Market: The company's P/E (-0.28) is higher than that of the market as a whole (-104.3).
5.3. P/BV
P/BV vs Sector: The company's P/BV (11.8) is lower than that of the sector as a whole (254.48).
P/BV vs Market: The company's P/BV (11.8) is lower than that of the market as a whole (72.17).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0.79) is lower than that of the sector as a whole (127.4).
P/S vs Market: The company's P/S indicator (0.79) is lower than that of the market as a whole (114).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-2.33) is higher than that of the sector as a whole (-27.32).
EV/Ebitda vs Market: The company's EV/Ebitda (-2.33) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -11.04% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-11.04%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (435.8%).
6.4. ROE
ROE vs Sector: The company's ROE (-275.74%) is lower than that of the sector as a whole (104.24%).
ROE vs Market: The company's ROE (-275.74%) is lower than that of the market as a whole (-6.22%).
6.6. ROA
ROA vs Sector: The company's ROA (-26.79%) is lower than that of the sector as a whole (-2.25%).
ROA vs Market: The company's ROA (-26.79%) is lower than that of the market as a whole (38.45%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-65.72%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (-65.72%) is lower than that of the market as a whole (9.79%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
